WATERTOWN, Mass., September 29, 2026--ai3Bio launches with $48M in Series A funding to reset the immune system at its root, advancing platforms targeting Th17 cells in vivo.
Vanderbilt Health researchers and colleagues have isolated human monoclonal antibodies from previously infected individuals ...
AC Immune has reported positive week-100 results from part 1 of its phase 2 VacSyn trial evaluating ACI-7104 in early-stage ...
Innovent Biologics, Inc. announced updated Phase 1 clinical data for IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma ...
The first three participants have been dosed in a nasal spray antibody trial for early-stage ALS, testing whether it can calm ...
Based on an integrated analysis of the efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) data from dose optimization cohorts receiving IBI3003 at 120, 360, and 540 µg/kg in the Phase 1 ...
Researchers at Washington University School of Medicine in St. Louis have developed a potential antibody-based approach to ...
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the first three participants have received their first dose of intranasal ...
A new study has found that immunoglobulin A (IgA), an antibody that protects the gut lining, may play a role in driving liver ...
The "gut-protective" antibody turns into an "inflammatory bomb" in the liver with excessive alcohol consumption... The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results